Event Driven Strategies Analyst Lafranchi discusses the Berry Global (BERY)/Amcor (AMCRY) (AMCR) merger on an Analyst/Industry conference call ...

BTIG analyst Carl Reichardt initiated coverage of BrightView (BV) with a Buy rating and $22 price target The company operates in a highly ...

As of the latest trading close, VSTM, a Healthcare sector stock, is trading -62.59% below its 52-week high but remains 153.33% above its 52-week low. The Average True Range (ATR) (14 days) of 0.4 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 7.01% of ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Investing.com -- According to a note from BTIG on Monday, the tech sector's ongoing weakness is raising concerns as markets ...

Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...

Investors should start looking at restaurant names that have timely setups, said Jonathan Krinsky, chief market technician at ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

BTIG analyst Andrew Harte is praising MicroStrategy's (NASDAQ:MSTR) plan announced at the end of October to raise $42B of ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did not surpass the 95% threshold for the primary ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...